Novo Nordisk isn’t putting all of its weight loss drug hopes in the same basket. Its acquisition of Inversago Pharma for up to $1 billion will bring a biotech whose lead drug candidate has early clinical trial data showing significant weight loss.
Novo Nordisk Aims to Succeed Where Sanofi Faltered Drugging a Weight-Loss Target
